CTx-1301 is designed to deliver 3 separate releases of medication at different times and in different ratios. Topline data were announced from a phase 3 trial evaluating CTx-1301 for the treatment of ...
Attention-deficit/hyperactivity disorder (ADHD) affects 3%–5% of children and about 2.5% of adults, though prevalence varies ...
A Prescription Drug User Fee Act target date of May 31, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback